Miniature transcriptomics-based ex vivo screening platform for personalized breast cancer therapy

Breast cancer is a highly heterogenous disease with each patient having disctinct disease profiles molacularly and genetically. Current standardized therapies overlook patient to patient variations, which leads to impaired therapeutic outcomes. To enable personalized medicine, we developed a miniature transcriptomics-based ex vivo compound screening platform for patient-derived physiologically relevant breast tissue. With gene expression signatures acquired from next generation sequencing (NGS), the system provides more precise prediction of patient reponses to hormones and drugs.

  • Field: Life Sciences and Bioengineering
  • Laboratory: UPBRI
  • Project leader: Yueyun Zhang
  • Budget: 30’000.00 CHF